5 Top Weekly NASDAQ Biotech Stocks: Novelion on Top
Novelion Therapeutics, EyePoint Pharmaceuticals, CytRx, Viking Therapeutics and AVEO Pharmaceuticals were last week’s top gainers.
Your trusted source for investing success
Your trusted source for investing success
Novelion Therapeutics, EyePoint Pharmaceuticals, CytRx, Viking Therapeutics and AVEO Pharmaceuticals were last week’s top gainers.
With Q1 2018 officially over, we’ve profiled the five top NASDAQ genetic stocks year-to-date. Here’s a look at what they’ve been up to.
Collaboration agreements between biotech companies are a way for companies to expand their drug portfolios without committing to a merger or acquisition.
Cardiome, Avid, XBiotech, Fennec and Compugen were last week’s five top-gaining NASDAQ biotech stocks. See what moved their share prices.
What is oncology investing? This sector can be intimidating for investors first getting into the space — here’s a brief breakdown of the ins and outs.
Second Sight, Juniper, Athersys, Aptose and ArQule were last week’s five top-gaining NASDAQ biotech stocks. See what moved their share prices.
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021. Here are 10 top stem cell companies on the NASDAQ.
March has been a busy month for Biogen with its voluntary withdrawal of Zinbryta and its acquisition of Pfizer’s PF-04958242.
Chi-Med, a China-based biopharmaceutical company, is making a name for itself within the oncology field at a global scale.
What is the best way to start investing in Alzheimer’s treatments? The space has proven difficult for companies to break into, but there are options.
Beleave Inc. (“Beleave” or the “Company”) (CSE:BE; OTCQX:BLEVF) is pleased to announce the appointment of Mark Heselton and Mark Miles to the Company’s Board of Directors.
“We see these additions as transformational and on behalf of the entire Company we would like to welcome Mark and Mark to the team.” Commented Beleave CEO Andrew Wnek, “Their
Alzheimer’s and other forms of dementia cost the US health care system over $259 billion in 2017, and may increase to over $1.1 trillion by 2050. Here’s a look at five Alzheimer disease treatment stocks for investor consideration.
This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to it’s year-to-date (YTD) increase. YTD the NBI increased 4.3 percent as of 1:00 p.m. EST Friday.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
Who are the top performing ETFs in the pharmaceuticals, biotechnology and life sciences markets year-to-date?
Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.
This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to it’s year-to-date (YTD) increase. YTD the NBI increased 4.3 percent as of 1:00 p.m. EST Friday.
A new report by Grandview Research suggests that global novel drug delivery systems (NDDS) in cancer therapies will reach $26.61 billion by 2025, growing at a compound annual growth rate of 22.9 percent from $4.31 billion in 2016.
Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
Catalyst Biosciences, Adverum Biotechnologies, MannKind, Galectin Therapeutics and Aptose Biosciences topped last week’s NASDAQ biotech stock list.
